Global "Transfusion Diagnostics Market" is expected to grow at a high CAGR of 6% during the forecasting period (2022-2029).
Blood transfusion is the process of transferring blood to the body. Transfusions are used for various medical conditions to replace lost components of the blood.
Blood transfusions are done to replace blood lost during surgery or due to a severe injury. A transfusion also may be done if the body can’t make blood properly because of an illness.
Blood transfusions are very common; almost Five million people receive a blood transfusion every year in the U.S.
The rising prevalence of blood cancer is one of the factors fueling the global transfusion diagnostics market.
According to the Leukemia Research Foundation, in 2018, more than 201,870 new cases of blood cancer are expected in the United States. Approximately 387,000 Americans are living with leukemia.
According to Cancer Research UK, there are around 9,900 new leukemia cases in the UK every year. Leukemia is the 12th most common cancer in the UK, accounting for 3% of all new cancer cases. In 2015, leukemia became 10th most common cancer in males with around 5,900 new cases in U.K, and 12th most common cancer in the female, with approximately 4,000 new cases in U.K.
Based on Application the global market for transfusion diagnostics is broadly segmented as by blood grouping, disease screening, and others.
Currently, disease screening is the dominant segment, and it accounts for approximately XX% of the market, due to the launch of new products and regulatory approval for disease screening device.
For instance, in April 2018, Sanquin and Abbott have signed a multiple-year contract for the supply of primary serological equipment and consumables, including Abbott’s Alinity s system, for blood and plasma screening. The agreement extends Abbott and Sanquin’s long-standing relationship of more than ten years.
In October 2018, Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Reader 24, a semi-automated blood typing instrument designed for medium- to small-volume laboratories.
The IH-Reader 24 automatically reads and transfers blood type and antibody screening results to Bio-Rad’s IH-Com patient data management software, offering improved efficiencies for transfusion medicine laboratories that use manual methods to test blood.
In January 2017, Abbott, have received CE Mark approval for its Alinity s System for blood and plasma screening and is now available in Europe and other countries that recognize CE Mark. The new testing solution is designed to screen blood and plasma faster and more efficiently within a smaller footprint.
In January 2016, Quotient Limited, a commercial-stage diagnostics company, has expanded the use of its MosaiQ transfusion diagnostics platform to include nucleic acid testing (NAT) for donor molecular disease screening.
The global transfusion diagnostics market is segmented into North America, Europe, Asia Pacific, South America, and ROW.
North America is dominating the global transfusion diagnostics market, due to the rising prevalence of blood cancer in the U.S, and regulatory approval for transfusion diagnostics, which is fueling the market growth.
For instance, according to the Leukemia Research Foundation, around 866,000 Americans were living with Hodgkin’s or non-Hodgkin’s lymphoma in 2018. An estimated 75,000 people are living with myelodysplastic syndromes in the United States. In 2017, there were 68,000 death cases from blood cancer in the U.S.
In November 2018, Immucor, Inc., a global leader in transfusion and transplantation diagnostics, has received FDA clearance for its fully automated NEO instrument. NEO Iris, Immucor’s sixth-generation immunohematology instrument, underscores Immucor’s unprecedented decades-long commitment to safely and fully automate the blood bank.
NEO Iris has test menu for mid- to high-volume, high-throughput blood testing performed in hospitals, donor centers, and clinical reference laboratories.
The regulatory approval, a strategic alliance between companies and the launch of new diagnostics, is one of the critical factor driving the global transfusion diagnostics market.
In January 2019, Immucor, Inc., a global leader in transfusion and transplantation diagnostics, has received approval by Health Canada for its fully automated Echo instrument, Echo Lumena, designed for the small to mid-volume laboratory segment, is Immucor’s fifth-generation immunohematology instrument and brings brilliant performance and more unambiguous test results.
In June 2017, Grifols, and Beckman Coulter Inc. entered into an exclusive, long-term agreement for the global distribution of Grifols’ hemostasis instruments, reagents, and consumables.
In August 2015, Bio-Rad Laboratories, Inc., has introduced IH-500, a fully automated random access system for blood typing and screening, providing small and medium-size transfusion medicine laboratories fast and reliable results in a 24/7 environment. The IH-500 system is available in Europe, Asia, Africa, Australia, and Latin America.
Get your free sample proposal with a single click!